Derek Lowe doesn't think RNAi will ever be useful in drug therapies, mainly because "nucleic acid-based therapies are just nightmarish to administer," he says. And he's not the only one. In a post at In the Pipeline, Lowe links to a recent CNBC story that details Leerink Swann's coverage of Alnylam. Analysts at the firm say that RNAi is "a drug development tool that we feel is more suited for research purposes than the development of therapeutics" and that Alynlam will probably never develop a successful drug.
Losing Its Luster
Aug 22, 2008